Merz Aesthetics is celebrating 15 years since its flagship brand Xeomin (incobotulinumtoxinA) was first approved for aesthetic use by the U.S. Food and Drug Administration (FDA). Xeomin is a double-purified, FDA-approved neurotoxin for the simultaneous treatment of upper facial lines—forehead lines, frown lines, and crow’s feet. To celebrate this 15-year U.S. milestone, 15 lucky winners will receive a year of free Xeomin treatments through Xperience+ by Merz Aesthetics U.S. patient loyalty program.
In addition, Merz Aesthetics is also launching a new, refreshed campaign for Xeomin in celebration of the milestone that aims to empower patients to ask for Xeominby showcasing Xeomin’s natural-looking results that allow people to express themselves. “Since its debut, Xeomin has been a trusted choice for patients and providers seeking effective, natural-looking results,” says Patrick Urban, president, North America, Merz Aesthetics. “Celebrating 15 years is more than a milestone—it’s a testament to our unwavering commitment to proven performance and advancing aesthetic care.”